Management Strategies and Outcomes in Primary Liver Angiosarcoma

Area of Science:

• Oncology
• Hepatology
• Sarcoma Research

Background:

• Primary hepatic angiosarcoma is a rare liver cancer originating from endothelial and fibroblastic tissues.
• It is characterized by a poor prognosis and a lack of standardized treatment protocols.
• This retrospective study analyzes clinical data from patients treated at an academic sarcoma center.

Purpose of the Study:

• To retrospectively analyze the clinical characteristics and treatment outcomes of primary liver angiosarcoma patients.
• To evaluate the effectiveness of various treatment modalities, including systemic therapy and local treatments.
• To identify factors influencing survival in patients with this rare liver cancer.

Main Methods:

• Screening of patients diagnosed with primary liver angiosarcoma between 2000 and 2022.
• Data collection from electronic medical records, including demographics, tumor characteristics, treatments, and outcomes.
• Statistical analysis using Python 3.0, with survival curves generated via Kaplan-Meier method and Lifelines Packages.

Main Results:

• A cohort of 23 patients (11 males, 12 females) aged 70-79 at diagnosis was analyzed.
• The median overall survival was 6 months, with 2- and 5-year survival rates at 38.6%.
• 71% received chemotherapy, 29% immunotherapy, and 14% underwent local treatment; three patients showed improved survival with diverse treatments.

Conclusions:

• Primary liver angiosarcoma demonstrates poor outcomes despite current treatments.
• Surgical resection with negative margins is the sole curative option, though often not feasible due to advanced disease presentation.
• Further research into novel systemic therapies is crucial for improving outcomes in this aggressive cancer.